胆汁酸浙贝乙素酯的合成、药理作用及镇咳机制的研究
|
摘要
随着药物化学、生物化学、结构化学、生理学、分子药理学等学科的发展和交叉渗透，人们逐渐认识并找出了许多药物发挥药理作用所依存的骨架结构，从而也产生了将具有相似生物活性的两类化合物进行结构拼合的设想，以期获得副作用更小、药效更加良好的新化合物。随着实践的不断深入，药物拼合作为一门理论逐渐为人们认识、接受并加以应用。拼合原理主要是指将两种化合物的结构拼合在一个分子内，或者将两个药物的骨架结构兼容在同一分子内，以期减小两种药物的毒副作用，求得二者作用的联合效应。
湖北贝母系百合科植物湖北贝母(Fritillaria hupehensis Hsiao et K．C．Hsia)的干燥鳞茎，具有清热化痰、止咳、散结之功效，在中国民间有悠久的用药历史，《中国药典》2000版和2005版均有收载。现代药理实验表明，湖北贝母总生物碱及其单体浙贝乙素均具有较强的镇咳和祛痰活性。蛇胆是一味名贵的中药材，系统的化学和药理实验证实其主要活性成分为牛磺胆汁酸及各种游离的胆汁酸。中药复方蛇胆川贝散是由川贝母和蛇胆两味中药组成，组方相对比较简单，具有清肺止咳、祛痰平喘的良好功效，在我国应用历史悠久，历版《中国药典》均有收载；但由于无法解决作用物质不明确所带来的质量无法控制等弊端，很难走向国际市场；而且由于组方的蛇胆和川贝母同属贵重药材，这类复方制剂还面临着中药材资源严重不足的问题。基于吴继洲教授对湖北贝母长达二十年的研究基础与石朝周教授对蛇胆十几年的研究基础，已经阐明贝母及蛇胆两味药材中的主要活性成分分别为异甾生物碱和各种胆汁酸。为了寻找具有高效低毒的镇咳、祛痰和平喘药物，本课题组以5种胆汁酸和浙贝乙素为原料，借鉴药物化学结构拼合的思路，开展了以下研究。
一、胆汁酸浙贝乙素酯合成路线的研究
1、酯键拼合的设计和合成以浙贝乙素和5种胆汁酸中的任意一种为原料，利用胆汁酸含有的羧基和浙贝乙素含有的羟基，在脱水剂(DCC)和催化剂(DMAP)条件下进行酯化反应，得到5个新化合物。
2、胆汁酸浙贝乙素酯的中试合成
经过波谱学及现代分析方法鉴定5个新化合物，确定合成的物质确实是目标化合物。随即大量合成系列胆汁酸浙贝乙素酯(胆酸浙贝乙素酯、鹅去氧胆酸浙贝乙素酯、熊去氧胆酸浙贝乙素酯、猪去氧胆酸浙贝乙素酯、去氧胆酸浙贝乙素酯)，为下一步5个新化合物的生物活性筛选打下基础。
二、胆汁酸浙贝乙素酯生物活性的筛选
在对5个胆汁酸浙贝乙素酯进行活性筛选的研究中，本课题组采用了小鼠氨水引咳、小鼠气管酚红排泌及豚鼠乙酰胆碱-组胺整体引喘三种动物模型，综合评价了5个新化合物的镇咳、祛痰和平喘活性。研究结果表明：在相同剂量下，胆酸浙贝乙素酯(CA-Ver)活性要明显强于其他的胆汁酸浙贝乙素酯，其中尤为值得关注的是，在小鼠氨水镇咳模型的筛选中，CA-Ver显示出了比磷酸可待因和原料药更强的镇咳活性。
三、胆汁酸浙贝乙素酯急性毒性的研究
对胆汁酸浙贝乙素酯的小鼠急性毒性研究结果表明：5个胆汁酸浙贝乙素酯小鼠灌胃给药的LD_(50)值超过6 g／kg，而且5个胆汁酸浙贝乙素酯小鼠腹腔注射给药的LD_(50)值超过3．5 g／kg，表明两类物质进行结构拼合是可以起到减毒作用的。
四、胆酸浙贝乙素酯镇咳机制的初步研究
1、胆酸浙贝乙素酯对小鼠大脑单胺类神经递质及其代谢产物的影响
采用RP-HPLC-FLD法，以磷酸可待因和氢溴酸右美沙芬为阳性对照药，测定了CA-Ver、浙贝乙素对小鼠脑部五种单胺类神经递质含量的影响。研究结果表明：阳性药右美沙芬的镇咳机制与单胺类神经递质5-HT有关，它能增加动物脑部5-HT的含量以达到镇咳效应；而CA-Ver、浙贝乙素和可待因的镇咳效应与5-羟色胺能机制无关。
2、胆酸浙贝乙素酯对中枢阿片受体能镇咳机理的研究
采用小鼠辣椒素引咳模型，借助非选择性阿片受体拮抗剂纳诺酮对小鼠进行预处理，探讨CA-Ver可能存在的中枢阿片受体能镇咳机制。研究结果显示阿片受体阻断剂纳诺酮能阻断CA-Ver镇咳效应的发挥，说明CA-Ver的镇咳机理与中枢阿片受体有关。
本论文对湖北贝母中的有效成分之一浙贝乙素和蛇胆中的活性成分胆汁酸进行酯键拼合的设计和合成，并对合成的5个新化合物进行了生物活性的筛选，以期寻找到增效减毒的镇咳新药。本课题组对活性最好的CA-Ver进行了较系统的药效学和机制的研究，为将其开发成为镇咳、祛痰新药奠定了坚实的基础。
Following the solo and cross-disciplinary development of biochemistry,medicinal chemistry,structural chemistry and physiology,the basic structuresof some drugs had been clearly elucidated,which were the core of theirbioactivities.In order to gain some new compounds with better bioactivity andattenuated toxicity,people attempted to combine two kinds of drugs throughionic bond or ester bond.Many famous drugs in clinic use such assultamicillin and benorilate were discovered through this way.Till now,“combination principle”has been an important idea and method in new drugdiscovery.
Hubeibeimu,listed in Pharmacopoeia of the People's Republic of China(Chp)2000 and Chp2005,is the dried bulb of Fritillaria hupehensis Hsiao etK.C.Hsia.Within the realm of Chinese medicine,Hubeibeimu has beenclaimed to resolve phlegm,stop cough,and clear away heat,and dispelaccumulation;it is widely used in Traditional Chinese Medicine.Recentpharmacological studies demonstrated that the total and single alkaloids (eg,verticinone) of this medicine have antitussive activity.Shedan is a valuableChinese crude drug.Systematic chemical and pharmacological researchstudies have confirmed that its main components are taurocholic acid andvarious kinds of free cholic acid.“Shedan-Chuanbei powder”,consisted ofSnake Bile (Chinese name“Shedan”) and Fritillariae Cirrhosae (Chinese name“Chuanbei”),is the most popular antitussive,expectorant andantiasthmatic formulation in Chinese communities.It has been used in clinicfor thousand years in China due to the positive potent therapeutic effects,lowtoxicity and minimal side effects.Therefore,it has been officially listed in theChinese Pharmacopoeia (1995,2000,and 2005).But the clinical applicationof Shedan-Chuanbei powder is now stringently limited because of theshortage of the two crude medicinal materials,especially for the sake ofanimal protection.In addition,the inherent defects of the most of the complexof traditional Chinese medicine such as the indistinct basal pharmacodynamicmaterials and the difficulties in quality control had blocked them heading intothe international medicinal market.Therefore,it prompts us to search for newbioactive substitutes for Shedan-Chuanbei powder for antitussive drugs.Basedon Prof.Wu Ji-zhou's nearly 20 years studies on the chemical constituents andthe bioactivities of the Fritillaria hupehensis and Prof.Shi Cao-zhou's morethan 10 years study on the bioactive constituents of Snake bile,theisosteroidal alkaloids and the bile acids were clearly elucidated as the twokind of major bioactive constituents respectively in bulbs of Fritillaria andSnake bile.In order to gain the new compounds with better bioactivity andattenuated toxicity,we tried to combine two kinds of drugs through ester bond.Enlightened with the“combination principle”in drug discovery,wesynthesized five novel esters of verticinone and bile acids,both of which arethe major bioactive components in Shedan-Chuanbei powder.And then we did a series of studies as follows:
ⅠStructure combination and synthetic procedure of bile acids-verticinone esters
In order to gain the new compounds with better bioactivity andattenuated toxicity,we tried to combine two kinds of drugs through ester bond.We synthesized five novel esters of verticinone and bile acids,named ascholic acid-verticinone ester (simplified as CA-Ver in the paper),chenodeoxycholic acid-verticinone ester (simplified as CDCA-Ver in thepaper),ursodeoxycholic acid-verticinone ester (simplified as UDCA-Ver inthe paper),hyodeoxycholic acid-verticinone ester (simplified as HDCA-Ver inthe paper),deoxycholic acid-verticinone ester (simplified as DCA-Ver in thepaper).Bile acids-verticinone esters were synthesized from bile acids andverticinone via esterification using DCC as the acid-activating agent,leadingto the linkage of the carboxylic acid group on C24 position of cholic acid withthe hydroxyl group on C3 position of verticinone.
CA-Ver,CDCA-Ver,UDCA-Ver,HDCA-Ver and DCA-Ver,five novelesters of verticinone and bile acids,were readily identified by comparison oftheir m.p,[α] _D~(20),IR,MS,~1H-NMR and ~(13)C-NMR data with their componentsteroid monomers.The synthesis of five novel esters are illustrated in Scheme1 (five steps,33% overall yield).Reaction of cholic acid with absolute MeOHfollowed by esterification resulted in the formation of methyl 3α,7α,12α-trihydroxy-5β-cholan-24-oate 1.Then reaction of 1 with TBDMSiCl via ether bond afforded the intermediate 2.Hydrolysis of the methyl ester groups of 2with 5% sodium hydroxide aqueous solution furnished 3.Then treatment of 3with verticinone in CH_2Cl_2 followed by esterification gave the compound 5α,14α-cevanin-6-O-20β-hydroxy-3β-yl-3α-tert-butyldimethylsilyloxy-7α,12α-dihydroxy-5β-cholan-24-oate 4.In this reaction,DMAP was used as a catalystand DCC as a dehydration agent.Finally,the deprotection reaction of 4 in 5 %HF aqueous solution gave the desired 5α,14α-cevanin-6-O-20β-hydroxy -3β-yl-3α,7α,12α-trihydroxy-5β-cholan-24-oate 5.The chemoselective esterificationreaction of 3 with verticinone in CH_2Cl_2 provided 4 in 58.9% yield.We thenevaluated the antitussive activity and the acute toxicity of the five ester-linkedcompounds.
ⅡScreening on the bioactivities of bile acids-verticinone esters
In the screening study of the bile acids-verticinone esters,we employedthree animal modes such as cough induced by ammonia water in mice,phenolred secretes in the trachea of mice and acetylcholine-histamine inducedasthma in guinea pigs to systematically evaluate the antitussive,expectorantand antiasthmatic effects of five bile acids-verticinone esters.The resultsshowed that CA-Ver had much more potent bioactivities than the other fouresters.Moreover,the much more potent antitussive effect of CA-Ver thancodeine phosphate also deserved advanced study.Based on the studies ofpharmacology,whether do the five ester-linked compounds have synergicpharmacodynamic action and attenuated toxicity compared with single verticinone and single bile acids?
ⅢThe acute toxicity of bile acids-verticinone esters
A further acute toxicity study showed that the LD_(50) values of the fiveester-linked compounds exceeded 3.5 g/kg by intraperitoneal injection in mice.There were no deaths or any signs of toxicity observed after oraladministration of single doses of the five ester-linked compounds at any doselevel up to the highest dose tested (6 g/kg),which was the no-observed-adserved-effect level (NOAEL).Uniformly,there were no deaths after theintraperitoneal injection at any dose level up to highest dose tested (3.5 g/kg).No mortalities had occurred during the study and whole observations did notindicate evidences of substance-related toxicity.So the acute toxicity of CA-Ver,CDCA-Ver,UDCA-Ver,HDCA-Ver and DCA-Ver were considered asunclassified,since a dose of 6 g/kg (by gavage) or 3.5 g/kg (by intraperitonealinjection) did not induce deaths or toxic symptoms.
ⅣThe antitussive mechanism of cholic acid-verticinone ester
1 The influences that CA-Ver made to the five kinds of monoamineneurotransmitters in mice's brain
By the reverse-phase HPLC method with fluorescent light detector,usingcodeine and dextromethorphan as positive drugs,we assayed the influencesthat CA-Ver and verticinone made to the five kinds of monanineneurotransmitters in mice's brain.The results indicated that the antitussivemechanism of dextromethorphan concered with monanine neurotransmitters 5-HT and it could increase the amount of 5-HT in animal's brain to producethe antitussive effects;while the antitussice effects of CA-Ver,verticinone andcodeine had no relationship with serotonergic mechanisms.
2 The central mechanism (modulated by opioid receptor) of CA-Ver
The test on capsaicin-induced cough model of mice pretreatment withnaloxone,a non-selective opioid receptor antagonist,was taken forobservation of CA-Ver's central antitussive mechanism.The studydemonstrated that p.o.administration of CA-Ver produced a dose-dependentantitussive effect in mice.The antitussive effect of CA-Ver was significantlyreduced by pretreatment naloxone.In a parallel study,codeine phosphate,oneof the most commonly used potent antitussive agents,was used as the positivecontrol.The antitussive effect of codeine phosphate,a centrally-acting,narcotic antitussive drug was also significantly reduced by pretreatmentnaloxone.These results indicate that the naloxone-sensitive opioid receptorplays an important role in mediating the antitussive effect of CA-Ver.All theresults indicated that the antitussive effects of CA-Ver had no relationshipwith serotonergic mechanisms but central opioid mechanism just as codeine.
Our present study not only synthesized the five novel esters of verticinoneand bile acids,which will be used as antitussive and expectorant agents infuture,it could also be an attempt at application structure combination idea tothe research and development of TCM,which may exploit a novel field ofnew drug design from TCM.Cumulatively,this study highlights a conjugated extension of esterification with verticinone and single bile acid and illustratesa potential benefit to structure combination of natural products.Furthermore,our current project could build the foundation to further study structure-activity relationship of verticinone and to develop a new antitussive drug innext step.
湖北贝母系百合科植物湖北贝母(Fritillaria hupehensis Hsiao et K．C．Hsia)的干燥鳞茎，具有清热化痰、止咳、散结之功效，在中国民间有悠久的用药历史，《中国药典》2000版和2005版均有收载。现代药理实验表明，湖北贝母总生物碱及其单体浙贝乙素均具有较强的镇咳和祛痰活性。蛇胆是一味名贵的中药材，系统的化学和药理实验证实其主要活性成分为牛磺胆汁酸及各种游离的胆汁酸。中药复方蛇胆川贝散是由川贝母和蛇胆两味中药组成，组方相对比较简单，具有清肺止咳、祛痰平喘的良好功效，在我国应用历史悠久，历版《中国药典》均有收载；但由于无法解决作用物质不明确所带来的质量无法控制等弊端，很难走向国际市场；而且由于组方的蛇胆和川贝母同属贵重药材，这类复方制剂还面临着中药材资源严重不足的问题。基于吴继洲教授对湖北贝母长达二十年的研究基础与石朝周教授对蛇胆十几年的研究基础，已经阐明贝母及蛇胆两味药材中的主要活性成分分别为异甾生物碱和各种胆汁酸。为了寻找具有高效低毒的镇咳、祛痰和平喘药物，本课题组以5种胆汁酸和浙贝乙素为原料，借鉴药物化学结构拼合的思路，开展了以下研究。
一、胆汁酸浙贝乙素酯合成路线的研究
1、酯键拼合的设计和合成以浙贝乙素和5种胆汁酸中的任意一种为原料，利用胆汁酸含有的羧基和浙贝乙素含有的羟基，在脱水剂(DCC)和催化剂(DMAP)条件下进行酯化反应，得到5个新化合物。
2、胆汁酸浙贝乙素酯的中试合成
经过波谱学及现代分析方法鉴定5个新化合物，确定合成的物质确实是目标化合物。随即大量合成系列胆汁酸浙贝乙素酯(胆酸浙贝乙素酯、鹅去氧胆酸浙贝乙素酯、熊去氧胆酸浙贝乙素酯、猪去氧胆酸浙贝乙素酯、去氧胆酸浙贝乙素酯)，为下一步5个新化合物的生物活性筛选打下基础。
二、胆汁酸浙贝乙素酯生物活性的筛选
在对5个胆汁酸浙贝乙素酯进行活性筛选的研究中，本课题组采用了小鼠氨水引咳、小鼠气管酚红排泌及豚鼠乙酰胆碱-组胺整体引喘三种动物模型，综合评价了5个新化合物的镇咳、祛痰和平喘活性。研究结果表明：在相同剂量下，胆酸浙贝乙素酯(CA-Ver)活性要明显强于其他的胆汁酸浙贝乙素酯，其中尤为值得关注的是，在小鼠氨水镇咳模型的筛选中，CA-Ver显示出了比磷酸可待因和原料药更强的镇咳活性。
三、胆汁酸浙贝乙素酯急性毒性的研究
对胆汁酸浙贝乙素酯的小鼠急性毒性研究结果表明：5个胆汁酸浙贝乙素酯小鼠灌胃给药的LD_(50)值超过6 g／kg，而且5个胆汁酸浙贝乙素酯小鼠腹腔注射给药的LD_(50)值超过3．5 g／kg，表明两类物质进行结构拼合是可以起到减毒作用的。
四、胆酸浙贝乙素酯镇咳机制的初步研究
1、胆酸浙贝乙素酯对小鼠大脑单胺类神经递质及其代谢产物的影响
采用RP-HPLC-FLD法，以磷酸可待因和氢溴酸右美沙芬为阳性对照药，测定了CA-Ver、浙贝乙素对小鼠脑部五种单胺类神经递质含量的影响。研究结果表明：阳性药右美沙芬的镇咳机制与单胺类神经递质5-HT有关，它能增加动物脑部5-HT的含量以达到镇咳效应；而CA-Ver、浙贝乙素和可待因的镇咳效应与5-羟色胺能机制无关。
2、胆酸浙贝乙素酯对中枢阿片受体能镇咳机理的研究
采用小鼠辣椒素引咳模型，借助非选择性阿片受体拮抗剂纳诺酮对小鼠进行预处理，探讨CA-Ver可能存在的中枢阿片受体能镇咳机制。研究结果显示阿片受体阻断剂纳诺酮能阻断CA-Ver镇咳效应的发挥，说明CA-Ver的镇咳机理与中枢阿片受体有关。
本论文对湖北贝母中的有效成分之一浙贝乙素和蛇胆中的活性成分胆汁酸进行酯键拼合的设计和合成，并对合成的5个新化合物进行了生物活性的筛选，以期寻找到增效减毒的镇咳新药。本课题组对活性最好的CA-Ver进行了较系统的药效学和机制的研究，为将其开发成为镇咳、祛痰新药奠定了坚实的基础。
Following the solo and cross-disciplinary development of biochemistry,medicinal chemistry,structural chemistry and physiology,the basic structuresof some drugs had been clearly elucidated,which were the core of theirbioactivities.In order to gain some new compounds with better bioactivity andattenuated toxicity,people attempted to combine two kinds of drugs throughionic bond or ester bond.Many famous drugs in clinic use such assultamicillin and benorilate were discovered through this way.Till now,“combination principle”has been an important idea and method in new drugdiscovery.
Hubeibeimu,listed in Pharmacopoeia of the People's Republic of China(Chp)2000 and Chp2005,is the dried bulb of Fritillaria hupehensis Hsiao etK.C.Hsia.Within the realm of Chinese medicine,Hubeibeimu has beenclaimed to resolve phlegm,stop cough,and clear away heat,and dispelaccumulation;it is widely used in Traditional Chinese Medicine.Recentpharmacological studies demonstrated that the total and single alkaloids (eg,verticinone) of this medicine have antitussive activity.Shedan is a valuableChinese crude drug.Systematic chemical and pharmacological researchstudies have confirmed that its main components are taurocholic acid andvarious kinds of free cholic acid.“Shedan-Chuanbei powder”,consisted ofSnake Bile (Chinese name“Shedan”) and Fritillariae Cirrhosae (Chinese name“Chuanbei”),is the most popular antitussive,expectorant andantiasthmatic formulation in Chinese communities.It has been used in clinicfor thousand years in China due to the positive potent therapeutic effects,lowtoxicity and minimal side effects.Therefore,it has been officially listed in theChinese Pharmacopoeia (1995,2000,and 2005).But the clinical applicationof Shedan-Chuanbei powder is now stringently limited because of theshortage of the two crude medicinal materials,especially for the sake ofanimal protection.In addition,the inherent defects of the most of the complexof traditional Chinese medicine such as the indistinct basal pharmacodynamicmaterials and the difficulties in quality control had blocked them heading intothe international medicinal market.Therefore,it prompts us to search for newbioactive substitutes for Shedan-Chuanbei powder for antitussive drugs.Basedon Prof.Wu Ji-zhou's nearly 20 years studies on the chemical constituents andthe bioactivities of the Fritillaria hupehensis and Prof.Shi Cao-zhou's morethan 10 years study on the bioactive constituents of Snake bile,theisosteroidal alkaloids and the bile acids were clearly elucidated as the twokind of major bioactive constituents respectively in bulbs of Fritillaria andSnake bile.In order to gain the new compounds with better bioactivity andattenuated toxicity,we tried to combine two kinds of drugs through ester bond.Enlightened with the“combination principle”in drug discovery,wesynthesized five novel esters of verticinone and bile acids,both of which arethe major bioactive components in Shedan-Chuanbei powder.And then we did a series of studies as follows:
ⅠStructure combination and synthetic procedure of bile acids-verticinone esters
In order to gain the new compounds with better bioactivity andattenuated toxicity,we tried to combine two kinds of drugs through ester bond.We synthesized five novel esters of verticinone and bile acids,named ascholic acid-verticinone ester (simplified as CA-Ver in the paper),chenodeoxycholic acid-verticinone ester (simplified as CDCA-Ver in thepaper),ursodeoxycholic acid-verticinone ester (simplified as UDCA-Ver inthe paper),hyodeoxycholic acid-verticinone ester (simplified as HDCA-Ver inthe paper),deoxycholic acid-verticinone ester (simplified as DCA-Ver in thepaper).Bile acids-verticinone esters were synthesized from bile acids andverticinone via esterification using DCC as the acid-activating agent,leadingto the linkage of the carboxylic acid group on C24 position of cholic acid withthe hydroxyl group on C3 position of verticinone.
CA-Ver,CDCA-Ver,UDCA-Ver,HDCA-Ver and DCA-Ver,five novelesters of verticinone and bile acids,were readily identified by comparison oftheir m.p,[α] _D~(20),IR,MS,~1H-NMR and ~(13)C-NMR data with their componentsteroid monomers.The synthesis of five novel esters are illustrated in Scheme1 (five steps,33% overall yield).Reaction of cholic acid with absolute MeOHfollowed by esterification resulted in the formation of methyl 3α,7α,12α-trihydroxy-5β-cholan-24-oate 1.Then reaction of 1 with TBDMSiCl via ether bond afforded the intermediate 2.Hydrolysis of the methyl ester groups of 2with 5% sodium hydroxide aqueous solution furnished 3.Then treatment of 3with verticinone in CH_2Cl_2 followed by esterification gave the compound 5α,14α-cevanin-6-O-20β-hydroxy-3β-yl-3α-tert-butyldimethylsilyloxy-7α,12α-dihydroxy-5β-cholan-24-oate 4.In this reaction,DMAP was used as a catalystand DCC as a dehydration agent.Finally,the deprotection reaction of 4 in 5 %HF aqueous solution gave the desired 5α,14α-cevanin-6-O-20β-hydroxy -3β-yl-3α,7α,12α-trihydroxy-5β-cholan-24-oate 5.The chemoselective esterificationreaction of 3 with verticinone in CH_2Cl_2 provided 4 in 58.9% yield.We thenevaluated the antitussive activity and the acute toxicity of the five ester-linkedcompounds.
ⅡScreening on the bioactivities of bile acids-verticinone esters
In the screening study of the bile acids-verticinone esters,we employedthree animal modes such as cough induced by ammonia water in mice,phenolred secretes in the trachea of mice and acetylcholine-histamine inducedasthma in guinea pigs to systematically evaluate the antitussive,expectorantand antiasthmatic effects of five bile acids-verticinone esters.The resultsshowed that CA-Ver had much more potent bioactivities than the other fouresters.Moreover,the much more potent antitussive effect of CA-Ver thancodeine phosphate also deserved advanced study.Based on the studies ofpharmacology,whether do the five ester-linked compounds have synergicpharmacodynamic action and attenuated toxicity compared with single verticinone and single bile acids?
ⅢThe acute toxicity of bile acids-verticinone esters
A further acute toxicity study showed that the LD_(50) values of the fiveester-linked compounds exceeded 3.5 g/kg by intraperitoneal injection in mice.There were no deaths or any signs of toxicity observed after oraladministration of single doses of the five ester-linked compounds at any doselevel up to the highest dose tested (6 g/kg),which was the no-observed-adserved-effect level (NOAEL).Uniformly,there were no deaths after theintraperitoneal injection at any dose level up to highest dose tested (3.5 g/kg).No mortalities had occurred during the study and whole observations did notindicate evidences of substance-related toxicity.So the acute toxicity of CA-Ver,CDCA-Ver,UDCA-Ver,HDCA-Ver and DCA-Ver were considered asunclassified,since a dose of 6 g/kg (by gavage) or 3.5 g/kg (by intraperitonealinjection) did not induce deaths or toxic symptoms.
ⅣThe antitussive mechanism of cholic acid-verticinone ester
1 The influences that CA-Ver made to the five kinds of monoamineneurotransmitters in mice's brain
By the reverse-phase HPLC method with fluorescent light detector,usingcodeine and dextromethorphan as positive drugs,we assayed the influencesthat CA-Ver and verticinone made to the five kinds of monanineneurotransmitters in mice's brain.The results indicated that the antitussivemechanism of dextromethorphan concered with monanine neurotransmitters 5-HT and it could increase the amount of 5-HT in animal's brain to producethe antitussive effects;while the antitussice effects of CA-Ver,verticinone andcodeine had no relationship with serotonergic mechanisms.
2 The central mechanism (modulated by opioid receptor) of CA-Ver
The test on capsaicin-induced cough model of mice pretreatment withnaloxone,a non-selective opioid receptor antagonist,was taken forobservation of CA-Ver's central antitussive mechanism.The studydemonstrated that p.o.administration of CA-Ver produced a dose-dependentantitussive effect in mice.The antitussive effect of CA-Ver was significantlyreduced by pretreatment naloxone.In a parallel study,codeine phosphate,oneof the most commonly used potent antitussive agents,was used as the positivecontrol.The antitussive effect of codeine phosphate,a centrally-acting,narcotic antitussive drug was also significantly reduced by pretreatmentnaloxone.These results indicate that the naloxone-sensitive opioid receptorplays an important role in mediating the antitussive effect of CA-Ver.All theresults indicated that the antitussive effects of CA-Ver had no relationshipwith serotonergic mechanisms but central opioid mechanism just as codeine.
Our present study not only synthesized the five novel esters of verticinoneand bile acids,which will be used as antitussive and expectorant agents infuture,it could also be an attempt at application structure combination idea tothe research and development of TCM,which may exploit a novel field ofnew drug design from TCM.Cumulatively,this study highlights a conjugated extension of esterification with verticinone and single bile acid and illustratesa potential benefit to structure combination of natural products.Furthermore,our current project could build the foundation to further study structure-activity relationship of verticinone and to develop a new antitussive drug innext step.
引文
[1]郭磊，谢强敏．镇咳药物的研究进展．国外医药·合成药 生化药 制剂分册，2000，21(1)：9-12
[2]Freestone C,Eccles R.Assessment of the antitussive efficacy of codeine in cough associated with common cold.J Pharm Pharmacol,1997,49:1045-1049
[3]Smith J,Owen E,Earis J,et al.Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease.JAllergy Clin Immunol， 2006,117:831-835
[4]Pavesi L,Subburaj S,Porter-Shaw K.Application and validation of a computerized cough acquisition system for objective monitoring of acute cough:a meta-analysis.Chest,2001,120:1121-1128
[5]KF Chung.Chronic cough:future directions in chronic cough:mechanisms and antitussives.Chronic Respiratory Disease,2007,4:159-165
[6]陈心启，夏光成．中药贝母名实考订．植物分类学报，1977，15(2)：40
[7]国家药典委员会．中华人民共和国药典．2005版．北京：化学工业出版社：286-287
[8]吴继洲，等．湖北贝母化学成分的研究Ⅲ．湖贝甲素甙的分离和鉴定．药学学报，1985，20(5)：372-376
[9]吴继洲，等．湖北贝母化学成分的研究Ⅴ．湖贝新的分离和鉴定．药学学报，1986，21(7)：546-550
[10]吴继洲，等．湖北贝母化学成分的研究Ⅳ．湖贝乙索、湖贝嗪的分离和鉴定及它们与湖贝甲素的相互转化．中草药，1986，17(8)：101-104
[11]吴继洲，等．湖北贝母化学成分的研究Ⅵ．应用于~(13)C谱解析湖贝啶的结构．中草药，1989，20(5)：194-199
[12]吴继洲，等．湖北贝母属植物化学成分的研究Ⅷ．湖贝甲素类衍生物的碳谱分析．中草药，1989，20(12)：530-531
[13]吴继洲，等．湖北贝母属植物化学成分的研究ⅩⅢ．湖贝甙的分离与结构解析． 药学学报，1991，26(11)：82
[14]杨曦亮．湖北贝母微量生物碱的结构研究及浙贝乙素衍生物LD_(50)的测定[硕士学位论文]．华中科技大学同济医学院，2006
[15]王振宇，段咸珍，孙有略．裕民贝母生物碱的含量测定及薄层层析．中药通报，1985，(10)：32-34
[16]钱伯初，许衡均．浙贝母碱和去氢浙贝母碱的镇咳镇静作用．药学学报， 1985，20：306-308
[17]熊玮，等．湖北贝母药理作用的初步研究．中草药，1986，17(3)：115-118
[18]李萍，等．贝母类中药的镇咳祛痰作用研究．四川医学院学报，1978，9(3)：44-47
[19]杨曦亮，等．浙贝乙素及其5种衍生物对小鼠的半数致死量测定．医药导报，2005，24(8)：660-662
[20]Williamson E.M.Pharmacognosy(15 edition) 2002:49-53
[21]Jia W,Gao WY,Yan YQ,et al.The rediscovery of ancient Chinese herbal formulas.Phytother Res,2004,18:681-686
[22]刘福利，等．结构拼合在药物研发中的应用．西北药学杂志，2005，20(2)：92-94
[23]朱维良，等．石杉碱甲类化合物定量构效关系的量子化学研究．中国药物化学杂志，1997，7：258-263
[24]Corey E J,Venkateswarlu A.Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives.J Am Chem Soc,1972,94:6190-6191
[25]Li Y,Dias JR.Dimeric and oligomeric steroids.Chem Rev,1997,97:283-304
[26]Li Y,Dias JR.Syntheses of linear dimeric and cyclic oligomeric cholate ester derivatives.Synthesis,1997,425-430
[27]Neton RF,Reynolds DP.An excellent reagent for the removal of the t-butyldimethylsilyl protecting group.Tetrahedron Lett,1979,20:3981-3982
[28]仇缀百．药物设计学．北京：高等教育出版社，1999，90
[29]杨曦亮，等．浙贝乙素及其5种衍生物对小鼠的半数致死量测定．医药导报，2005，24(8)：660-662
[30]张鹏．湖北贝母总生物碱及其制剂的药学研究[博士学位论文]．华中科技大学同济医学院，2006
[31]张勇慧，等．湖北贝母镇咳、祛痰、平喘药效部位的筛选．中草药，2003，34:1016-1018
[32]Lin G,Li P,Li SL,et al.Chromatographic analysis of Fritillaria isosteroidal alkaloids,the active ingredients of Beimu,the antitussive traditional Chinese medicinal herb.J Chromatography A,2001,935:321-338
[33]李培峰，等．鹅去氧胆酸的平喘及抗炎作用机理研究．中国中药杂志，2004，29：349-352
[34]Lin ZM,Zhou XQ.Immunoregulation effect of UDCA.Chin Hepatol,2002,7:113-114
[35]Baker JF,Blickenstaff RT.Intramolecular catalysis-Ⅷ.Effects on the acetylation of the 7α-hydroxyl group of steroids.A proton nuclear magnetic resonance rate method.J Org Chem,1975,40:1579-1586
[36]Li Y,Dias JR.Syntheses of α- and β-dimers of lithocholic acid esters.Org Prep Proc lnt,1996,28:203-209
[37]徐叔云，卞如濂．药理实验方法学．第3版．北京：人民卫生出版社，2002：1359，1362-1363，1380
[38]中华人民共和国卫生部药政局．新药(西药)临床前研究指导原则汇编．北京：人民卫生出版社，1973：76，80，86
[39]Adcock J J,Schneider C,Smith TW.Effects of codeine,morphine and a novel opioid pentapeptide BW443C,On cough,nociception and ventilation in the unanaesthetized guinea pig.Br J Pharmacol,1988,93:93-100
[40]国家食品药品管理局编著．化学药物急性毒性试验技术指导原则．北京：2005
[41]国家食品药品管理局编著．中药、天然药物急性毒性研究技术指导原则．北京：2005，3-7
[42]Xu FZ,Chen C,Zhang YH,et al.Synthesis and antitussive evaluation of verticinonecholic acid salt,a novel and potential cough therapeutic agent.Acta Pharmacol Sin(中国药理学报)，2007，28(10)：1591-1596
[43]杨曦亮，张勇慧，阮汉利，等．浙贝乙素及其5种衍生物对小鼠的半数致死量测定．医药导报，2005，24(8)：660-662
[44]陆伦根，茅益民．熊去氧胆酸的药学和毒理学及作用机制．康哲肝癌信息网(新药研究论坛专栏)，2005，9
[45]何秀玲，关红．牛磺鹅去氧胆酸研究进展．畜牧与饲料科学，2008，3：57-60
[46]陈奇．中药药理研究方法学．第1版．北京：人民卫生出版社，1993：112-119
[47]Zhang JL,Wang H,Pi HF,et al.Structural analysis and antitussive evaluation of five novel esters of verticinone and bile acids.Steroids,2009,74(4-5):424-434
[48]Donald CB.Current and future centrally acting antitussives.Respir Physiol,2006,152:349-355
[49]Donald CB.Mechanisms of action central and peripheral antitussive drugs.Pulm Pharmacol,1996,9:357-364
[50]苏桂兰，王薇．中枢性与末梢性镇咳药．中国药店，2002，18：89
[51]Dicpinigaitis,PV.Potential new cough therapies.Pulm Pharmacol Ther,2004,17:459-462
[52]Kamei J.Role of opioidergic and serotonergic Mechanisms in cough and antitussives.Pulm Pharmacol,1996,9:349-356
[53]Sandra MR,ralyn JM.The pharmacology of cough.Trend Pharmacol Sci,2004,25:569-576
[54]Kamei J,Ogawa M,Kasuya Y.Monoamines and the mechanisms of action of antitussive drugs in rats.Arch int Pharmacodyn Ther,1987,290:117-127
[55]中医研究院针灸经络研究所生化组．脑组织中5羟色胺、5羟吲哚醋酸、去甲肾上腺素和多巴胺的同时提取和荧光分光光度测定法．医药参考，1975，20(7)：38-44
[56]谢笑龙，杨丹莉，李志梅，等．大鼠脑内儿茶酚胺类递质及其代谢物的同时提取及反向高效液相测定法．遵义医学院学报，2004，27(5)：447-449
[57]Peroutka SJ,Snyder SH.Multiple serotonin receptors:different binding of[~3H]5-hydroxytryptamine,[~3H]lysergic acid diethylamine and[~3H]spiperidol.Mol Pharmacol,1979,16:687-699
[58]Hoyer D,Claker DE,Fozard JR,et al.International Union of Pharmacology classification of receptors for 5-hydroxytrptamine(serotonin).Pharmacol Rev,1994,46:157-203
[59]Takemura K,Takada K,Mameya S,et al.Regional and functional differences of 5- hydroxytryptamine-receptor subtypes in guinea pig stomach.Jan J Pharmacol,1999,79(1):41-49
[60]Bruinvels AT,Landwehrmeyer B,Gustafson EL,et al.Localization of 5-HT1B,5-HT1D_α,5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain.Neuropharmacol,1994,33(3-4):367-386
[61]Kamei J,Hosokawa T,Yanaura S,et al.Involvement of central serotonergic mechanisms in the cough reflex.Jan JPharmacol,1986,42:531-538
[62]Kamei J,Morita K,Saitoh A,et al.The antitussive effects of endomorphin-1 and endomorphin-2 in mice.Eur J Pharmacol,2003,467:219-222
[63]Kamei J,Iwamoto Y,Kawashima N,Suzuki T,Nagase H,Misawa M,Kasuya Y.Possible involvement of μ_2-mediated mechanisms in μ-mediated antitussive activity in the mouse.Neurosci Lett,1993,149:169-172
[64]吴康松，谢强敏，沈文会，等．辣椒素吸入小鼠咳嗽模型和记录装置的建立．中国药理学通报，2002，18(1)：109-111
[65]Kamei J,Iwamoto Y,Suzuki T,Misawa M,Nagase H,Kasuya Y.The role of the μ_2-opioid receptor in the antitussive effect of morphine in μ_1-opioid receptor-deficient CXBK mice.Eur J Pharmacol,1993,240:99-101
[66]Heyman JS,Mulvaney SA,Mosberg HI,Porreca F.Opioid δ receptor involvement in supraspinal and spinal antinociception in mice.Brain Res,1987,420:100-108
[67]Junzo K.Delta-opioid receptor antagonists as a new concept for central acting antitussive drugs.Pulm Pharmacol Ther,2002,15:235-240
[68]Kamei J,Iwamoto Y,Misawa M,et al.Effects of rimcazole,a specific antagonist of sigma sites,in the antitussive effects of nonnarcotic antitussive drugs.Eur J Pharmacol,1993,242:209-211
[69]Epstein OI,Kovaleva VL,Zak MS,et al.Ultralow doses of antibodies to inflammatory mediators:antitussive properties of antibodies to bradykinin,histamine,and serotonin.Bull Exp Biol Med,2003,135:146-149
[70]Kamei J,Mori T,Igarashi H,et al.Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs.Res Commun Chem Pathol Pharmacol,1992,76: 371-374
[71] Kamei J, Ogawa M, Kasuya Y. Monoamines and the mechanisms of action of antitussive drugs in rats. Arch Int Pharmacodyn Ther, 1987, 290:117-127
[72] Duffy RA. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs, 2004, 9: 9-21
[73] Hay DW, Giardina GA, Griswold DE, et al. Nonpeptide tachykinin receptor antagonists. Ⅲ. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper- reactivity in guinea pigs. J Pharmacol Exp Ther, 2002, 300: 314-323
[74] Manocha A, Sharma KK, Mediratta PK. Possible mechanism involved in the anticonvulsant action of butorphanol in mice. Pharmacol Biochem Behav, 2003, 74: 343- 350
[75] Undem BJ, Carr MJ. Pharmacology of airway afferent nerve activity. Respir Res 2001,2:234-244
[76] Chung KF. Drugs to suppress cough.. Expert Opin Investig Drugs, 2005, 14: 19-27
[77] McLeod RL, Fernandez X, Correll CC, et al. TRPV1 antagonists attenuate antigen- provoked cough in ovalbumin sensitized guinea pigs. Cough, 2006,2: 10
[78] Mafrica F, Fodale V. Opioids and Down's syndrome. J Opioid Manag, 2006, 2: 93-98
[79] Kamei J. Delta-opioid receptor antagonists as a new concept for central acting antitussive drugs. Pulm Pharmacol Ther, 2002, 15: 235-240
[80] Zhang JL, Wang H, Chen C, et al.Addictive evaluation of cholic acid-verticinone ester, a potential cough therapeutic agent with agonist action of opioid receptor. Acta Pharmacol Sin, 2009, 30(5): 559-566
[1]刘吉开．由世界制药20强的在研项目分析看天然药物开发前景．中草药，2000，31(7)： 481-487
[2]Harvty A．收获天然产物的硕果[英]．国外医学(药学分册)，2002，29(3)：184-185
[3]王普善．天然产物在新药发现中的地位与机会(Ⅰ)——重新审视天然产物药物发现战略．中国医药导刊，2005，7(5)：385-387
[4]Newman DJ,Cragg GM.Natural products as sources of new drugs over the last 25 years.J Nat Prod,2007,70:461-477
[5]Newman DJ,Cragg GM,Snader KM.Natural products as sources of new drugs over the period 1981-2002.JNat Prod,2003,66:1022-1037
[6]Cragg GM,Newman D J,Snader KM.Natural products in drug discovery and development.J Nat Prod,1997,60:52-60
[7]王普善．天然产物在新药发现中的地位与机会(Ⅱ)——天然产物仍是发现新药的一个重要领域．中国医药导刊，2006，8(2)：133-136
[8]Ebert U,Oertel R,Kirch W.Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects.Chin Pharmacol Ther,2000,67(5):538-548
[9]Moller H J,Hampel H,Heggerl U,et al.Double-blind,randomized,placebocontrolled chemical trial on the efficacy and tolerability of a physostigrnine patch in patients with senile dementia of the Alzheimer type.Pharmacopsychiatry,1999,32:99-106
[10]Xu SS,Cai ZY,Qu ZW,et al.Huperzine-A in capsules and tablets for treating patients with Alzheimer disease.Acta Pharmacol Sin,1999,20(6):486-490
[11]Scott JJ,Goa KL.Galantamine:a review of its use in Alzheimer's disease.Drugs,2000,60(5):1095-1122
[12]Rinehart KL.Antitumor compounds from tunicates.Med Res Rev,2000,20:1-27
[13]Pettit GR.Progress in the discovery of biosynthetic anticancer drugs.J Nat Prod,1996,59(8):812-821
[14]Faolkner DJ.Highlights of marine natural products chemistry(1972-1999).Nat ProdRep,2000,17:1-6
[15]Zonder JA,Shields AF,Zalupski M,et al.A Phase Ⅱ trial of bryostatin 1 in the treatment of metastatic colorectal cancer.Clin Cancer Res,2001,7:38-42
[16]Paglinro L,Daliani D,Amato R,et al.A Phase Ⅱ trial of bryostatin 1 for patients with metastatic renal cell carcinoma.Cancer,2000,9:615-618
[17]Mastbergen SC,Duivenvoorden I,Verstecgh RT,et al.Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs.Anticancer Res,2000,20:1833-1838
[18]Varterasian ML,Mohammad RM,Shurafa MS,et al.Phase Ⅱ trial of bryostatin 1 in patients with replaced low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.Clin Cancer Res,2000,6:825-828
[19]Giannakakou P,Fojo T.Discodermolide:just another microtuble-stabilizing agent?No!A lesson in synergy.Clin Cancer Res,2000,6:1613-1615
[20]Vaishampayan U,Glode M,Du W,et al.Phase Ⅱ study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.Clin Cancer Res,2000,6:4205-4208
[21]Curman D,Cinel B,Williams DE,et al.Inhibition of the G_2 DNA damage checkpoint and of protein kinases Chk 1 and Chk 2 by the marine sponge alkaloid debromohymenialdisine.J Biol Chem,2001,276(21):17914-17919
[22]丁健．抗肿瘤药物的研究进展．中国新药杂志，2000，9：149-150
[23]张克，张月琴，魏玉珍等．桔青霉No．68菌株的发酵产物对微管的表达．中国抗生素杂志，2000，25：220-225
[24]李晓红，龚炳永，朱宝泉．微生物来源的免疫抑制剂研究现状．国外医药-抗生素分册，2000，21：271-277
[25]Martinez EJ,Corey EJ.A new,more efficient,and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents.Organic lett,2000,2:993-996
[26]Nicolaou KC，Vourloumis D,Winssinger N,et al.The art and science of total synthesis at the dawn ofthe twenty-first century.Angew Chem Int EdEngl,2000,39:44
[27]Hayward MM,Roth RM,Duffy KJ,et al.Total synthesis of altohyrtin A.Angew
Chem Int Ed Engl,1998,37:192
[28]Balog A,Meng D,Katmenecka T,et al.Total synthesis of(-)-epothilone A.Angew
Chem Int Ed Engl,1996,35:2801
[29]田少雷，赵树林，朱爱堂等．去甲斑蝥素氨基酸衍生物的合成与抗癌活性．药
学学报，1993，28(11)：870-875
[30]方茵，田少雷，李克庆等．去甲斑蝥素去氧脱氢物类似物的合成与抗癌活性．
药学学报，1993，28(12)：931-935
[31]王志光，马维勇，黄火等．鬼臼毒素类的化学与抗肿瘤活性研究．中国药物化
学杂志，1993，3(1)：17-22
[32]尹述凡，庄武，马维勇等．4-S-(5-酰氨基-1，3，4-噻二唑-2-基)-4-脱氧-4‘-去甲
基表鬼臼毒素衍生物的合成与抗肿瘤活性．药学学报，1993，28(10)：762-765
[33]刘明生，谷黎红，陈英杰等．齐墩果酸磷酸酯单钠的合成．中国药物化学杂志，
1993，3(1)：42-43
[34]Heather J,Honda T.Bioorg & Med Chem Lett,1997,7(13):1769-1772
[35]岳琴，方起程，梁晓天．紫杉醇的半合成．药学学报，1996，31(12)：91 1-917
[36]Kingston DG.Studies on the chemistry of Taxol.Pure & Appl Chem,1998,70:331-
334
[37]Chaudhary AG,Gharpure MM,Rimoldi JM,et al.Unexpectedly facile hydrolysis of
the 2-benzoate group of Taxol and syntheses of analogs with increased activities.J Am
Chem Soc,1994,116:4097-4098
[38]Dimmock JR,Sidhu KK,Chen M.Evaluation of some Mannich bases of
cycloalkanones and related compounds for cytotoxic activity.Eur JMed Chem,1993,28(4):
313-322
[39]朴日阳，刘百里，计志忠等．2-羟基-3-甲基-环戊-2-烯酮Mannich碱衍生物的
合成及其抗癌活性．中国药物化学杂志，1998，8(3)：157-162
[40]姚伟星，夏国瑾，江明性等．粉防己碱对犬缺血心肌的保护作用．药学学报，
1995，30(9)：651
[41]黄文龙，黄忱亚，彭司勋等．粉防己碱的还原裂解及其裂解产物的活性．中国 药科大学学报，1988，19(2)：81
[42]黄文龙，张惠斌，彭司勋．粉防己碱裂解酚性副产物的分离和鉴别．中国药科大学学报，1993，24(5)：269
[43]黄文龙，宋学勤，彭司勋等．取代四氢异喹啉衍生物的合成及其生物活性．药学学报，1990，25(11)：815
[44]郁敏，华维一，彭司勋．四氢异喹啉类化合物的合成和抗血小板聚集活性．药学学报，1995，30(2)：112
[45]许国友，彭司勋，华维一．取代苄基/萘甲基异喹啉类及有关季铵衍生物的合成与生物活性．药学学报，1994，29(2)：95
[46]Dong H,Lee CM,Peng SX,et al.Cardiovascular effects of substituted tetrahydroisoquinolines in rats.Br J Pharmacol,1992,107(1):262
[47]黄忱亚，冯玫华，彭司勋．四氢原小檗碱型季铵化合物的合成及其参数的测定．中国药科大学学报，1988，19(4)：249
[48]王端芳，许国友，华维一等．四氢小檗碱季铵化合物的合成及其抗心律失常活性．中国药物化学杂志，1996，6(4)：234
[49]李德有，高志军，纪庆娥．7-甲氧基-3’-N，N-二烷胺甲基-4’-羟基异黄酮的合成．中国药物化学杂志，1991，1(2)：38-42
[50]李德有，高志军，纪庆娥．7-氯和6-氯-7-甲氧基-3’-(N，N-二乙胺甲基)-4’-羟基异黄酮的合成．中国药物化学杂志，1992，2(1)：23-28
[51]王存英，张德勇．(+)去甲氧基红葱甲素和(+)去甲氧基红葱乙素的合成．药学学报，1993，28(2)：146-151
[52]李国栋，周全，赵长文等．青蒿素类药物的研究现状．中国药学杂志，1998，33(7)：385-389
[53]李英，张惠斌，叶云鹏．二氢青蒿素和11-羟基二氢青蒿素的酯类衍生物的合成．中国药物化学杂志，1995，5(2)：127-130
[54]梁洁，李英．青蒿素芳香醚类衍生物的合成．中国药物化学杂志，1996，6(1)：22-30
[55]徐美忠，谢毓元．棉酚类似物的合成研究．中国药物化学杂志，1992，2(4)：22-25
[56]张席妮，谢毓元．棉酚类似物的合成研究Ⅱ．中国药物化学杂志，1991，1(2)：20-
[57]马鹏程，闫玮，吕杨．雷公藤内酯酮半合成方法研究．中国药科大学学报，1996，27(6)：562-568
[58]李金柱，李伟．水飞蓟宾的结构改造研究进展．中华实用中西医杂志，2007，20(20)：1818-1819
[59]梁基智，林洁茹，谭海荣．水飞蓟宾对抗大鼠酒精性脂肪肝改善肝功能的作用．中国临床康复，2006，10(7)：183-185
[60]Vladimir K,Kubisch J,Sedmera P,et al.Glycosylation of silybin.J Chem Soc,Perkin Transactions 1,1997,17:2467-2474
[61]Pavel K.Antioxidant properties of silybin glycosides.Phytotherapy Research,2002,16(2):533-539
[62]李绍顺，吴岳平，赵明等．松柏醇的合成方法改进．中国药物化学杂志，1993，3(1)：47-53
[63]曾繁星，蒋华良，杨玉社等．石杉碱甲的合成及结构改造研究进展．化学进展，2000，12(1)：63-76
[64]何煦昌，王兆瀛，黎运龙等．5-取代氨甲基-2(1H)-吡啶酮和5-取代氨基-5，6，7，8-四氢喹诺酮的合成．中国药物化学杂志，1994，4(4)：257-263
[65]徐振荣，何煦昌．(+)-失二碳石杉碱甲类似物的合成．药学学报，1996，31(4)：258-266
[66]籍秀娟，张福荣．靛玉红类化合物的抗肿瘤作用及构效关系的研究．药学学报，1985，20(2)：137-139
[67]许旋，罗一帆，陈子超等．抗癌药物靛玉红及其衍生物定量构效关系的研究．数理医药杂志，1999，12(1)：43-44
[68]孙存济，嵇汝运等．南瓜子氨酸类似物及其衍生物的合成．药学学报，1985，20(3)：214-218
[2]Freestone C,Eccles R.Assessment of the antitussive efficacy of codeine in cough associated with common cold.J Pharm Pharmacol,1997,49:1045-1049
[3]Smith J,Owen E,Earis J,et al.Effect of codeine on objective measurement of cough in chronic obstructive pulmonary disease.JAllergy Clin Immunol， 2006,117:831-835
[4]Pavesi L,Subburaj S,Porter-Shaw K.Application and validation of a computerized cough acquisition system for objective monitoring of acute cough:a meta-analysis.Chest,2001,120:1121-1128
[5]KF Chung.Chronic cough:future directions in chronic cough:mechanisms and antitussives.Chronic Respiratory Disease,2007,4:159-165
[6]陈心启，夏光成．中药贝母名实考订．植物分类学报，1977，15(2)：40
[7]国家药典委员会．中华人民共和国药典．2005版．北京：化学工业出版社：286-287
[8]吴继洲，等．湖北贝母化学成分的研究Ⅲ．湖贝甲素甙的分离和鉴定．药学学报，1985，20(5)：372-376
[9]吴继洲，等．湖北贝母化学成分的研究Ⅴ．湖贝新的分离和鉴定．药学学报，1986，21(7)：546-550
[10]吴继洲，等．湖北贝母化学成分的研究Ⅳ．湖贝乙索、湖贝嗪的分离和鉴定及它们与湖贝甲素的相互转化．中草药，1986，17(8)：101-104
[11]吴继洲，等．湖北贝母化学成分的研究Ⅵ．应用于~(13)C谱解析湖贝啶的结构．中草药，1989，20(5)：194-199
[12]吴继洲，等．湖北贝母属植物化学成分的研究Ⅷ．湖贝甲素类衍生物的碳谱分析．中草药，1989，20(12)：530-531
[13]吴继洲，等．湖北贝母属植物化学成分的研究ⅩⅢ．湖贝甙的分离与结构解析． 药学学报，1991，26(11)：82
[14]杨曦亮．湖北贝母微量生物碱的结构研究及浙贝乙素衍生物LD_(50)的测定[硕士学位论文]．华中科技大学同济医学院，2006
[15]王振宇，段咸珍，孙有略．裕民贝母生物碱的含量测定及薄层层析．中药通报，1985，(10)：32-34
[16]钱伯初，许衡均．浙贝母碱和去氢浙贝母碱的镇咳镇静作用．药学学报， 1985，20：306-308
[17]熊玮，等．湖北贝母药理作用的初步研究．中草药，1986，17(3)：115-118
[18]李萍，等．贝母类中药的镇咳祛痰作用研究．四川医学院学报，1978，9(3)：44-47
[19]杨曦亮，等．浙贝乙素及其5种衍生物对小鼠的半数致死量测定．医药导报，2005，24(8)：660-662
[20]Williamson E.M.Pharmacognosy(15 edition) 2002:49-53
[21]Jia W,Gao WY,Yan YQ,et al.The rediscovery of ancient Chinese herbal formulas.Phytother Res,2004,18:681-686
[22]刘福利，等．结构拼合在药物研发中的应用．西北药学杂志，2005，20(2)：92-94
[23]朱维良，等．石杉碱甲类化合物定量构效关系的量子化学研究．中国药物化学杂志，1997，7：258-263
[24]Corey E J,Venkateswarlu A.Protection of hydroxyl groups as tert-butyldimethylsilyl derivatives.J Am Chem Soc,1972,94:6190-6191
[25]Li Y,Dias JR.Dimeric and oligomeric steroids.Chem Rev,1997,97:283-304
[26]Li Y,Dias JR.Syntheses of linear dimeric and cyclic oligomeric cholate ester derivatives.Synthesis,1997,425-430
[27]Neton RF,Reynolds DP.An excellent reagent for the removal of the t-butyldimethylsilyl protecting group.Tetrahedron Lett,1979,20:3981-3982
[28]仇缀百．药物设计学．北京：高等教育出版社，1999，90
[29]杨曦亮，等．浙贝乙素及其5种衍生物对小鼠的半数致死量测定．医药导报，2005，24(8)：660-662
[30]张鹏．湖北贝母总生物碱及其制剂的药学研究[博士学位论文]．华中科技大学同济医学院，2006
[31]张勇慧，等．湖北贝母镇咳、祛痰、平喘药效部位的筛选．中草药，2003，34:1016-1018
[32]Lin G,Li P,Li SL,et al.Chromatographic analysis of Fritillaria isosteroidal alkaloids,the active ingredients of Beimu,the antitussive traditional Chinese medicinal herb.J Chromatography A,2001,935:321-338
[33]李培峰，等．鹅去氧胆酸的平喘及抗炎作用机理研究．中国中药杂志，2004，29：349-352
[34]Lin ZM,Zhou XQ.Immunoregulation effect of UDCA.Chin Hepatol,2002,7:113-114
[35]Baker JF,Blickenstaff RT.Intramolecular catalysis-Ⅷ.Effects on the acetylation of the 7α-hydroxyl group of steroids.A proton nuclear magnetic resonance rate method.J Org Chem,1975,40:1579-1586
[36]Li Y,Dias JR.Syntheses of α- and β-dimers of lithocholic acid esters.Org Prep Proc lnt,1996,28:203-209
[37]徐叔云，卞如濂．药理实验方法学．第3版．北京：人民卫生出版社，2002：1359，1362-1363，1380
[38]中华人民共和国卫生部药政局．新药(西药)临床前研究指导原则汇编．北京：人民卫生出版社，1973：76，80，86
[39]Adcock J J,Schneider C,Smith TW.Effects of codeine,morphine and a novel opioid pentapeptide BW443C,On cough,nociception and ventilation in the unanaesthetized guinea pig.Br J Pharmacol,1988,93:93-100
[40]国家食品药品管理局编著．化学药物急性毒性试验技术指导原则．北京：2005
[41]国家食品药品管理局编著．中药、天然药物急性毒性研究技术指导原则．北京：2005，3-7
[42]Xu FZ,Chen C,Zhang YH,et al.Synthesis and antitussive evaluation of verticinonecholic acid salt,a novel and potential cough therapeutic agent.Acta Pharmacol Sin(中国药理学报)，2007，28(10)：1591-1596
[43]杨曦亮，张勇慧，阮汉利，等．浙贝乙素及其5种衍生物对小鼠的半数致死量测定．医药导报，2005，24(8)：660-662
[44]陆伦根，茅益民．熊去氧胆酸的药学和毒理学及作用机制．康哲肝癌信息网(新药研究论坛专栏)，2005，9
[45]何秀玲，关红．牛磺鹅去氧胆酸研究进展．畜牧与饲料科学，2008，3：57-60
[46]陈奇．中药药理研究方法学．第1版．北京：人民卫生出版社，1993：112-119
[47]Zhang JL,Wang H,Pi HF,et al.Structural analysis and antitussive evaluation of five novel esters of verticinone and bile acids.Steroids,2009,74(4-5):424-434
[48]Donald CB.Current and future centrally acting antitussives.Respir Physiol,2006,152:349-355
[49]Donald CB.Mechanisms of action central and peripheral antitussive drugs.Pulm Pharmacol,1996,9:357-364
[50]苏桂兰，王薇．中枢性与末梢性镇咳药．中国药店，2002，18：89
[51]Dicpinigaitis,PV.Potential new cough therapies.Pulm Pharmacol Ther,2004,17:459-462
[52]Kamei J.Role of opioidergic and serotonergic Mechanisms in cough and antitussives.Pulm Pharmacol,1996,9:349-356
[53]Sandra MR,ralyn JM.The pharmacology of cough.Trend Pharmacol Sci,2004,25:569-576
[54]Kamei J,Ogawa M,Kasuya Y.Monoamines and the mechanisms of action of antitussive drugs in rats.Arch int Pharmacodyn Ther,1987,290:117-127
[55]中医研究院针灸经络研究所生化组．脑组织中5羟色胺、5羟吲哚醋酸、去甲肾上腺素和多巴胺的同时提取和荧光分光光度测定法．医药参考，1975，20(7)：38-44
[56]谢笑龙，杨丹莉，李志梅，等．大鼠脑内儿茶酚胺类递质及其代谢物的同时提取及反向高效液相测定法．遵义医学院学报，2004，27(5)：447-449
[57]Peroutka SJ,Snyder SH.Multiple serotonin receptors:different binding of[~3H]5-hydroxytryptamine,[~3H]lysergic acid diethylamine and[~3H]spiperidol.Mol Pharmacol,1979,16:687-699
[58]Hoyer D,Claker DE,Fozard JR,et al.International Union of Pharmacology classification of receptors for 5-hydroxytrptamine(serotonin).Pharmacol Rev,1994,46:157-203
[59]Takemura K,Takada K,Mameya S,et al.Regional and functional differences of 5- hydroxytryptamine-receptor subtypes in guinea pig stomach.Jan J Pharmacol,1999,79(1):41-49
[60]Bruinvels AT,Landwehrmeyer B,Gustafson EL,et al.Localization of 5-HT1B,5-HT1D_α,5-HT1E and 5-HT1F receptor messenger RNA in rodent and primate brain.Neuropharmacol,1994,33(3-4):367-386
[61]Kamei J,Hosokawa T,Yanaura S,et al.Involvement of central serotonergic mechanisms in the cough reflex.Jan JPharmacol,1986,42:531-538
[62]Kamei J,Morita K,Saitoh A,et al.The antitussive effects of endomorphin-1 and endomorphin-2 in mice.Eur J Pharmacol,2003,467:219-222
[63]Kamei J,Iwamoto Y,Kawashima N,Suzuki T,Nagase H,Misawa M,Kasuya Y.Possible involvement of μ_2-mediated mechanisms in μ-mediated antitussive activity in the mouse.Neurosci Lett,1993,149:169-172
[64]吴康松，谢强敏，沈文会，等．辣椒素吸入小鼠咳嗽模型和记录装置的建立．中国药理学通报，2002，18(1)：109-111
[65]Kamei J,Iwamoto Y,Suzuki T,Misawa M,Nagase H,Kasuya Y.The role of the μ_2-opioid receptor in the antitussive effect of morphine in μ_1-opioid receptor-deficient CXBK mice.Eur J Pharmacol,1993,240:99-101
[66]Heyman JS,Mulvaney SA,Mosberg HI,Porreca F.Opioid δ receptor involvement in supraspinal and spinal antinociception in mice.Brain Res,1987,420:100-108
[67]Junzo K.Delta-opioid receptor antagonists as a new concept for central acting antitussive drugs.Pulm Pharmacol Ther,2002,15:235-240
[68]Kamei J,Iwamoto Y,Misawa M,et al.Effects of rimcazole,a specific antagonist of sigma sites,in the antitussive effects of nonnarcotic antitussive drugs.Eur J Pharmacol,1993,242:209-211
[69]Epstein OI,Kovaleva VL,Zak MS,et al.Ultralow doses of antibodies to inflammatory mediators:antitussive properties of antibodies to bradykinin,histamine,and serotonin.Bull Exp Biol Med,2003,135:146-149
[70]Kamei J,Mori T,Igarashi H,et al.Serotonin release in nucleus of the solitary tract and its modulation by antitussive drugs.Res Commun Chem Pathol Pharmacol,1992,76: 371-374
[71] Kamei J, Ogawa M, Kasuya Y. Monoamines and the mechanisms of action of antitussive drugs in rats. Arch Int Pharmacodyn Ther, 1987, 290:117-127
[72] Duffy RA. Potential therapeutic targets for neurokinin-1 receptor antagonists. Expert Opin Emerg Drugs, 2004, 9: 9-21
[73] Hay DW, Giardina GA, Griswold DE, et al. Nonpeptide tachykinin receptor antagonists. Ⅲ. SB 235375, a low central nervous system-penetrant, potent and selective neurokinin-3 receptor antagonist, inhibits citric acid-induced cough and airways hyper- reactivity in guinea pigs. J Pharmacol Exp Ther, 2002, 300: 314-323
[74] Manocha A, Sharma KK, Mediratta PK. Possible mechanism involved in the anticonvulsant action of butorphanol in mice. Pharmacol Biochem Behav, 2003, 74: 343- 350
[75] Undem BJ, Carr MJ. Pharmacology of airway afferent nerve activity. Respir Res 2001,2:234-244
[76] Chung KF. Drugs to suppress cough.. Expert Opin Investig Drugs, 2005, 14: 19-27
[77] McLeod RL, Fernandez X, Correll CC, et al. TRPV1 antagonists attenuate antigen- provoked cough in ovalbumin sensitized guinea pigs. Cough, 2006,2: 10
[78] Mafrica F, Fodale V. Opioids and Down's syndrome. J Opioid Manag, 2006, 2: 93-98
[79] Kamei J. Delta-opioid receptor antagonists as a new concept for central acting antitussive drugs. Pulm Pharmacol Ther, 2002, 15: 235-240
[80] Zhang JL, Wang H, Chen C, et al.Addictive evaluation of cholic acid-verticinone ester, a potential cough therapeutic agent with agonist action of opioid receptor. Acta Pharmacol Sin, 2009, 30(5): 559-566
[1]刘吉开．由世界制药20强的在研项目分析看天然药物开发前景．中草药，2000，31(7)： 481-487
[2]Harvty A．收获天然产物的硕果[英]．国外医学(药学分册)，2002，29(3)：184-185
[3]王普善．天然产物在新药发现中的地位与机会(Ⅰ)——重新审视天然产物药物发现战略．中国医药导刊，2005，7(5)：385-387
[4]Newman DJ,Cragg GM.Natural products as sources of new drugs over the last 25 years.J Nat Prod,2007,70:461-477
[5]Newman DJ,Cragg GM,Snader KM.Natural products as sources of new drugs over the period 1981-2002.JNat Prod,2003,66:1022-1037
[6]Cragg GM,Newman D J,Snader KM.Natural products in drug discovery and development.J Nat Prod,1997,60:52-60
[7]王普善．天然产物在新药发现中的地位与机会(Ⅱ)——天然产物仍是发现新药的一个重要领域．中国医药导刊，2006，8(2)：133-136
[8]Ebert U,Oertel R,Kirch W.Physostigmine reversal of midazolam-induced electroencephalographic changes in healthy subjects.Chin Pharmacol Ther,2000,67(5):538-548
[9]Moller H J,Hampel H,Heggerl U,et al.Double-blind,randomized,placebocontrolled chemical trial on the efficacy and tolerability of a physostigrnine patch in patients with senile dementia of the Alzheimer type.Pharmacopsychiatry,1999,32:99-106
[10]Xu SS,Cai ZY,Qu ZW,et al.Huperzine-A in capsules and tablets for treating patients with Alzheimer disease.Acta Pharmacol Sin,1999,20(6):486-490
[11]Scott JJ,Goa KL.Galantamine:a review of its use in Alzheimer's disease.Drugs,2000,60(5):1095-1122
[12]Rinehart KL.Antitumor compounds from tunicates.Med Res Rev,2000,20:1-27
[13]Pettit GR.Progress in the discovery of biosynthetic anticancer drugs.J Nat Prod,1996,59(8):812-821
[14]Faolkner DJ.Highlights of marine natural products chemistry(1972-1999).Nat ProdRep,2000,17:1-6
[15]Zonder JA,Shields AF,Zalupski M,et al.A Phase Ⅱ trial of bryostatin 1 in the treatment of metastatic colorectal cancer.Clin Cancer Res,2001,7:38-42
[16]Paglinro L,Daliani D,Amato R,et al.A Phase Ⅱ trial of bryostatin 1 for patients with metastatic renal cell carcinoma.Cancer,2000,9:615-618
[17]Mastbergen SC,Duivenvoorden I,Verstecgh RT,et al.Cell cycle arrest and clonogenic tumor cell kill by divergent chemotherapeutic drugs.Anticancer Res,2000,20:1833-1838
[18]Varterasian ML,Mohammad RM,Shurafa MS,et al.Phase Ⅱ trial of bryostatin 1 in patients with replaced low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.Clin Cancer Res,2000,6:825-828
[19]Giannakakou P,Fojo T.Discodermolide:just another microtuble-stabilizing agent?No!A lesson in synergy.Clin Cancer Res,2000,6:1613-1615
[20]Vaishampayan U,Glode M,Du W,et al.Phase Ⅱ study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma.Clin Cancer Res,2000,6:4205-4208
[21]Curman D,Cinel B,Williams DE,et al.Inhibition of the G_2 DNA damage checkpoint and of protein kinases Chk 1 and Chk 2 by the marine sponge alkaloid debromohymenialdisine.J Biol Chem,2001,276(21):17914-17919
[22]丁健．抗肿瘤药物的研究进展．中国新药杂志，2000，9：149-150
[23]张克，张月琴，魏玉珍等．桔青霉No．68菌株的发酵产物对微管的表达．中国抗生素杂志，2000，25：220-225
[24]李晓红，龚炳永，朱宝泉．微生物来源的免疫抑制剂研究现状．国外医药-抗生素分册，2000，21：271-277
[25]Martinez EJ,Corey EJ.A new,more efficient,and effective process for the synthesis of a key pentacyclic intermediate for production of ecteinascidin and phthalascidin antitumor agents.Organic lett,2000,2:993-996
[26]Nicolaou KC，Vourloumis D,Winssinger N,et al.The art and science of total synthesis at the dawn ofthe twenty-first century.Angew Chem Int EdEngl,2000,39:44
[27]Hayward MM,Roth RM,Duffy KJ,et al.Total synthesis of altohyrtin A.Angew
Chem Int Ed Engl,1998,37:192
[28]Balog A,Meng D,Katmenecka T,et al.Total synthesis of(-)-epothilone A.Angew
Chem Int Ed Engl,1996,35:2801
[29]田少雷，赵树林，朱爱堂等．去甲斑蝥素氨基酸衍生物的合成与抗癌活性．药
学学报，1993，28(11)：870-875
[30]方茵，田少雷，李克庆等．去甲斑蝥素去氧脱氢物类似物的合成与抗癌活性．
药学学报，1993，28(12)：931-935
[31]王志光，马维勇，黄火等．鬼臼毒素类的化学与抗肿瘤活性研究．中国药物化
学杂志，1993，3(1)：17-22
[32]尹述凡，庄武，马维勇等．4-S-(5-酰氨基-1，3，4-噻二唑-2-基)-4-脱氧-4‘-去甲
基表鬼臼毒素衍生物的合成与抗肿瘤活性．药学学报，1993，28(10)：762-765
[33]刘明生，谷黎红，陈英杰等．齐墩果酸磷酸酯单钠的合成．中国药物化学杂志，
1993，3(1)：42-43
[34]Heather J,Honda T.Bioorg & Med Chem Lett,1997,7(13):1769-1772
[35]岳琴，方起程，梁晓天．紫杉醇的半合成．药学学报，1996，31(12)：91 1-917
[36]Kingston DG.Studies on the chemistry of Taxol.Pure & Appl Chem,1998,70:331-
334
[37]Chaudhary AG,Gharpure MM,Rimoldi JM,et al.Unexpectedly facile hydrolysis of
the 2-benzoate group of Taxol and syntheses of analogs with increased activities.J Am
Chem Soc,1994,116:4097-4098
[38]Dimmock JR,Sidhu KK,Chen M.Evaluation of some Mannich bases of
cycloalkanones and related compounds for cytotoxic activity.Eur JMed Chem,1993,28(4):
313-322
[39]朴日阳，刘百里，计志忠等．2-羟基-3-甲基-环戊-2-烯酮Mannich碱衍生物的
合成及其抗癌活性．中国药物化学杂志，1998，8(3)：157-162
[40]姚伟星，夏国瑾，江明性等．粉防己碱对犬缺血心肌的保护作用．药学学报，
1995，30(9)：651
[41]黄文龙，黄忱亚，彭司勋等．粉防己碱的还原裂解及其裂解产物的活性．中国 药科大学学报，1988，19(2)：81
[42]黄文龙，张惠斌，彭司勋．粉防己碱裂解酚性副产物的分离和鉴别．中国药科大学学报，1993，24(5)：269
[43]黄文龙，宋学勤，彭司勋等．取代四氢异喹啉衍生物的合成及其生物活性．药学学报，1990，25(11)：815
[44]郁敏，华维一，彭司勋．四氢异喹啉类化合物的合成和抗血小板聚集活性．药学学报，1995，30(2)：112
[45]许国友，彭司勋，华维一．取代苄基/萘甲基异喹啉类及有关季铵衍生物的合成与生物活性．药学学报，1994，29(2)：95
[46]Dong H,Lee CM,Peng SX,et al.Cardiovascular effects of substituted tetrahydroisoquinolines in rats.Br J Pharmacol,1992,107(1):262
[47]黄忱亚，冯玫华，彭司勋．四氢原小檗碱型季铵化合物的合成及其参数的测定．中国药科大学学报，1988，19(4)：249
[48]王端芳，许国友，华维一等．四氢小檗碱季铵化合物的合成及其抗心律失常活性．中国药物化学杂志，1996，6(4)：234
[49]李德有，高志军，纪庆娥．7-甲氧基-3’-N，N-二烷胺甲基-4’-羟基异黄酮的合成．中国药物化学杂志，1991，1(2)：38-42
[50]李德有，高志军，纪庆娥．7-氯和6-氯-7-甲氧基-3’-(N，N-二乙胺甲基)-4’-羟基异黄酮的合成．中国药物化学杂志，1992，2(1)：23-28
[51]王存英，张德勇．(+)去甲氧基红葱甲素和(+)去甲氧基红葱乙素的合成．药学学报，1993，28(2)：146-151
[52]李国栋，周全，赵长文等．青蒿素类药物的研究现状．中国药学杂志，1998，33(7)：385-389
[53]李英，张惠斌，叶云鹏．二氢青蒿素和11-羟基二氢青蒿素的酯类衍生物的合成．中国药物化学杂志，1995，5(2)：127-130
[54]梁洁，李英．青蒿素芳香醚类衍生物的合成．中国药物化学杂志，1996，6(1)：22-30
[55]徐美忠，谢毓元．棉酚类似物的合成研究．中国药物化学杂志，1992，2(4)：22-25
[56]张席妮，谢毓元．棉酚类似物的合成研究Ⅱ．中国药物化学杂志，1991，1(2)：20-
[57]马鹏程，闫玮，吕杨．雷公藤内酯酮半合成方法研究．中国药科大学学报，1996，27(6)：562-568
[58]李金柱，李伟．水飞蓟宾的结构改造研究进展．中华实用中西医杂志，2007，20(20)：1818-1819
[59]梁基智，林洁茹，谭海荣．水飞蓟宾对抗大鼠酒精性脂肪肝改善肝功能的作用．中国临床康复，2006，10(7)：183-185
[60]Vladimir K,Kubisch J,Sedmera P,et al.Glycosylation of silybin.J Chem Soc,Perkin Transactions 1,1997,17:2467-2474
[61]Pavel K.Antioxidant properties of silybin glycosides.Phytotherapy Research,2002,16(2):533-539
[62]李绍顺，吴岳平，赵明等．松柏醇的合成方法改进．中国药物化学杂志，1993，3(1)：47-53
[63]曾繁星，蒋华良，杨玉社等．石杉碱甲的合成及结构改造研究进展．化学进展，2000，12(1)：63-76
[64]何煦昌，王兆瀛，黎运龙等．5-取代氨甲基-2(1H)-吡啶酮和5-取代氨基-5，6，7，8-四氢喹诺酮的合成．中国药物化学杂志，1994，4(4)：257-263
[65]徐振荣，何煦昌．(+)-失二碳石杉碱甲类似物的合成．药学学报，1996，31(4)：258-266
[66]籍秀娟，张福荣．靛玉红类化合物的抗肿瘤作用及构效关系的研究．药学学报，1985，20(2)：137-139
[67]许旋，罗一帆，陈子超等．抗癌药物靛玉红及其衍生物定量构效关系的研究．数理医药杂志，1999，12(1)：43-44
[68]孙存济，嵇汝运等．南瓜子氨酸类似物及其衍生物的合成．药学学报，1985，20(3)：214-218